Key Takeaways
- FY25 revenue +16%, PAT doubled: Revenue growth was broad-based across CDMO and CRO, while a 105% PAT jump was supported by operating leverage and cost discipline.
- One-time provision hit Q4 margins: A prudent provision against a customer de-stocking situation caused a 70% YoY jump in other expenses, masking underlying margin improvement toward the 28-30% long-term target.
- Capex cycle accelerating on pipeline visibility: FY26 capex of close to ₹700 crores, funding a ~30% capacity increase, is driven by molecules scaling up and new modality build-outs in peptides, ADCs, and oligos.
- Supply chain shift is the dominant demand driver: Management attributes current demand more to the structural shift of pharma supply chains into India than to any unusual sector-wide upcycle.
- What to watch next quarter: Whether the ₹34 crore provision is recovered, the pace of new capacity coming online in November, and any tariff-driven customer behavior changes as the situation settles.
Business Model & Competitive Position
- Integrated discovery-to-commercial model: The company spans discovery, development, and commercial manufacturing, a footprint management claims is uniquely differentiated and deep enough across the value chain to create upside potential.
- Customer concentration trend favors integration: Large pharma customers are consolidating footprints with fewer partners who can integrate discovery with manufacturing and development, a trend that benefits Sai Life's model.
- Diversification timeline spans four years: The supply chain shift began in early 2021 with commercial molecules moving to India, followed by R&D pipeline migration, then discovery business shifting from large pharma, while biotech migration slowed.
- Overseas operations declining as a share: Indian capacity additions mean overseas operations, which are largely fixed cost and fixed revenue, will continue to decline as a proportion of the total, reducing their cost impact over time.
- Manchester running at high utilization: The Manchester site is at high capacity with incremental people being added where possible, but no dramatic expansion planned; the combination with Indian capacity provides key differentiation through best practices across both sites.
Krishna Kanumuri: "I don't think anybody has this footprint at this point. So I think our business model is uniquely different enough and we're deep enough across the value chain, which is really creating this upside potential for us."
CDMO Performance & Pipeline
- FY25 CDMO growth was modest: Certain molecules scaled up for the first time and follow-on orders resulted in lower growth than the prior year, though commercial product volume has since increased with visibility for further scaling next year.
- Confidence built on dual drivers: Growth confidence comes from commercial products scaling up plus FTE deals currently being worked on that lead into scale-up opportunities, generating manufacturing revenue alongside R&D revenues.
- Asset turns comparable to peers: The company is an investment-heavy base with fairly new capacities, and asset turns are reasonably comparable to the rest of the market among expanding players.
- Cyclicality is inherent to the model: Management acknowledges the industry is cyclical and does not have straight-line growth projections, with outcomes tied to timing and success or failure of commercial launches.
- New capacity adds ~30% to the base: One part of new manufacturing capacity comes online in November, another half in May, increasing total capacity by close to 30% for the year.
Krishna Kanumuri: "It's basically timing of commercial launch, successful or failure of commercial launch. So, essentially, we're an industry which is basically cyclical and doesn't have a straight-line growth projection."
CRO & Discovery Growth
- CRO revenues grew ~26% in FY25: Growth was driven by pharma revenue increasing from around 30% to 37-38% of the CRO mix, while biotech customers appear well-funded despite a tough macro environment.
- Discovery business growing irrespective of market: The company has grown discovery for three consecutive years regardless of market conditions, driven by the combination of the Boston site and India operations.
- Biotech environment remains hard to read: Customers are reacting to tariff news and the situation is still fluid, making the near-term biotech funding and spending environment uncertain.
Krishna Kanumuri: "But the environment is still very tough and very hard to read right now because they're just reacting to the Tariff news and it's all relatively new."
New Modalities Investment
- Three conjugation modalities in focus: Customers have identified peptide conjugates, ADC conjugates, and nucleotide conjugates as key areas, which together with traditional small molecules account for 80-90% of the pipeline today.
- Investing ₹50-70 crores in new modalities: Capex is directed at building discovery, development, and clinical supply capabilities across peptides, ADCs, and oligos, with people and lab capacity coming on board alongside early-phase material supply assets.
- Following customers, not molecules: The strategy is to build capabilities where existing customers are directing their pipelines, rather than chasing individual molecule classes independently.
- Build-out will be gradual: Most pharma assets in these modalities are early phase, so the ramp will be a gradual process rather than a direct entry into commercial supply.
- Oligonucleotide commercial assets exist: The company already has commercial assets on the oligonucleotide side through its Amidites business.
Krishna Kanumuri: "In this way, we're not following the molecule, we're following our customer, if I would put it that way."
Margins & Financial Management
- EBITDA margin improved to 25% from 20%: The full-year improvement was supported by better operating leverage, cost optimization, and increased capacity utilization, moving closer to the long-term 28-30% target.
- Q4 provision masked underlying performance: A one-time prudent provision taken on bad debt and contract assets from a customer de-stocking situation caused a 70% YoY jump in other expenses, with 100% provision taken against the exposure.
- Provision recovery still being pursued: The ₹34 crore provision was against a delayed billing, taken as a matter of prudence while the company continues to work on recovery.
- First-half margins structurally lower: CDMO fixed costs make first-half EBITDA margins lower than the second half, though this seasonality should smoothen as the business grows with larger commercial volume products.
- Debt repayment completed: The planned ₹720 crores debt repayment from IPO proceeds has been completed, with lower interest costs expected from FY26.
- ROCE commitment being met: The company committed to mid-to-high-teen ROCE during the IPO process and continues to meet that target.
Demand Environment & Supply Chain Shift
- Supply chain shift is the dominant factor: Current demand is mostly attributable to the structural migration of pharma supply chains into India rather than any unusual sector-wide dynamics.
- Tariff and MFN impact too early to assess: Management declined to quantify any impact, noting the situation remains fluid and no customers are making decisions yet, with any effects likely very long-term rather than short-term in nature.
- Pharma relationship build-out may level off: Management expects a period of leveling off over the next two years as pharma companies continue building relationships in India, which will grow over time.
Krishna Kanumuri: "Right now, it's mostly supply chain shift. I think that's what you have to attribute it to more than anything else. It's not like the sector is doing any more different than usual, but I think the supply chain shift is a major factor."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Long-term EBITDA margin | 28% to 30% | Over the next couple of years, within a 3-5 year period |
| Long-term revenue growth CAGR | 15% to 20% | Over a 3-5 year period |
| FY26 capex | Close to ₹700 crores, with ~₹550 crores currently planned; funded from internal accruals, debt, and remaining IPO money | FY26 |
| Capacity increase | Close to ~30% addition from new manufacturing capacity | One part in November, another half in May |
| ROCE | Mid-to-high-teen ROCE | Ongoing commitment, currently being met |
| Interest costs | Lower interest costs expected | From FY26 |
| New modalities capex | ₹50 crores to ₹70 crores | Ongoing build-out |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue from operations (FY25) | ₹1,695 cr, +16% YoY from ₹1,465 cr in FY24 |
| EBITDA (FY25) | ₹425 cr, +42% YoY from ₹300 cr in FY24 |
| EBITDA margin (FY25) | 25%, up from 20% in FY24; long-term target 28–30% |
| Profit after tax (FY25) | ₹170 cr, +105% YoY from ₹83 cr in FY24 |
| ROCE (FY25) | 12%, up from 10% in FY24 |
| Revenue mix (FY25) | CDMO 63%, CRO 37% |
| CRO revenue growth (FY25) | ~26% YoY |
| Large pharma share in CRO | 37–38%, up from ~30% last year |
| Large pharma share in CDMO | ~70% large pharma, 30% biotech |
| Capacity utilization (FY25) | 67% |
| Capex (FY25) | ₹408 cr |
| Planned capex (FY26) | ₹700+ cr, with ~₹550 cr based on current visibility; 60–65% manufacturing, 35% R&D |
| Maintenance capex | ~₹70 cr |
| New modalities capex (FY26) | ₹50–70 cr for peptides, ADCs, oligos |
| Working capital days (FY25) | 117 days |
| Debt repayment (FY25) | ₹720 cr completed from IPO proceeds |
| FTE strength growth (FY25) | ~27% YoY; FY26 expected growth 12–15% |
| Overseas centers revenue (FY25) | $14–15 mn, EBITDA profitable |
| Discovery business split | 60% discovery chemistry, 40% biology services (DMPK and biology) |
| Q4 one-time provision | ~₹34 cr against delayed customer billing, 2% impact on FY25 revenue |
| Q1 FY25 EBITDA margin | 9%, versus 25–27% in subsequent quarters due to CDMO seasonality |
| Capacity increase (FY26) | ~30% from new manufacturing lines coming online |